Antiparasitic Activity of Auranofin against Pathogenic Naegleria fowleri

Area of Science:

• Infectious Diseases
• Pharmacology
• Neuroscience

Background:

• Primary amoebic meningoencephalitis (PAM) is a rare but almost universally fatal infection caused by the free-living amoeba Naegleria fowleri.
• Current treatment options for PAM are limited and often ineffective, highlighting the urgent need for novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential amoebicidal activity of auranofin, a gold-containing antirheumatoid drug, against the human pathogenic amoeba Naegleria fowleri.
• To evaluate the effects of auranofin on Naegleria fowleri viability, metabolic activity, and cell membrane integrity.

Main Methods:

• Naegleria fowleri cultures were treated with varying concentrations of auranofin (0.75-3.0 μg/ml).
• Amoeba counts, metabolic activity (e.g., using metabolic assays), and cell permeability were assessed to determine the drug's efficacy.

Main Results:

• Auranofin treatment significantly reduced Naegleria fowleri amoeba counts in a dose-dependent manner.
• Metabolic activity of the amoebae was decreased, and cell permeability was increased following auranofin exposure.
• These effects were observed at biologically relevant concentrations of auranofin.

Conclusions:

• Auranofin exhibits potent amoebicidal activity against Naegleria fowleri.
• The findings suggest that auranofin could be a potential therapeutic agent for treating primary amoebic meningoencephalitis.
• Further research is warranted to explore the clinical application of auranofin in PAM patients.